Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 700 shares, a drop of 87.9% from the January 15th total of 5,800 shares. Based on an average trading volume of 9,000 shares, the days-to-cover […]
Samsung Bioepis suspends development for its biosimilar referencing Eylea (aflibercept); the FDA updates its labeling recommendations for interchangeable biosimilars; Alvotech receives a Form 483 after the FDA reinspected its Iceland-based manufacturing facility.
By Dean Seal Shares of Alvotech jumped after the company said its drug candidates AVT02 and AVT04 could be approved in the coming months now that U.S..
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today.